BRIEF published on 08/06/2024 at 21:12, 1 year 10 months ago Evotec Provides Updated Fiscal Guidance for 2024 Adjusted EBITDA Revenue Forecast Sustainable Growth 2024 Guidance Evotec
BRIEF published on 08/06/2024 at 21:12, 1 year 10 months ago Evotec fournit des orientations fiscales mises à jour pour 2024 EBITDA Ajusté Prévisions De Revenus Evotec Une Croissance Durable Orientation 2024
BRIEF published on 08/06/2024 at 21:09, 1 year 10 months ago Evotec SE Updates Financial Guidance for 2024 Adjusted EBITDA Revenue Forecast Financial Guidance Evotec SE R&D Expenditure
BRIEF published on 08/06/2024 at 21:09, 1 year 10 months ago Evotec SE met à jour ses prévisions financières pour 2024 Evotec SE EBITDA Ajusté Conseils Financiers Prévisions De Revenus Dépenses De R&D
PRESS RELEASE published on 08/06/2024 at 21:07, 1 year 10 months ago Evotec provides guidance update Evotec SE refines guidance for fiscal year 2024, expecting moderate revenue growth, reduced R&D expenditures, and adjusted EBITDA; aims for sustainable profitable growth amid market challenges Adjusted EBITDA Revenue Growth Evotec SE Guidance Update R&D Expenditures
PRESS RELEASE published on 08/06/2024 at 21:04, 1 year 10 months ago EQS-Adhoc: Evotec SE provides guidance update Evotec SE refines guidance for fiscal year 2024, expecting revenue and EBITDA adjustments due to slower sales conversion and margin pressures, focusing on sustainable growth EBITDA Revenue Evotec SE Sustainable Growth Guidance Update
BRIEF published on 07/10/2024 at 07:35, 1 year 11 months ago Evotec and Pfizer Collaborate to Advance Drug Discovery in France Drug Discovery Metabolic Diseases Evotec Pfizer Infectious Diseases
BRIEF published on 07/10/2024 at 07:35, 1 year 11 months ago Evotec et Pfizer collaborent pour faire progresser la découverte de médicaments en France Maladies Métaboliques Evotec Découverte De Médicament Pfizer Maladies Infectieuses
PRESS RELEASE published on 07/10/2024 at 07:30, 1 year 11 months ago Evotec and Pfizer collaborate to advance drug discovery in France Evotec SE collaborates with Pfizer to focus on early discovery research for metabolic and infectious diseases in France. The multi-year agreement includes research support and potential milestones Drug Discovery Evotec SE France Pfizer Metabolic And Infectious Diseases
BRIEF published on 07/08/2024 at 14:05, 1 year 11 months ago Just – Evotec Biologics Expands Tech Partnership for Biosimilars with Sandoz Partnership Biosimilars Evotec Sandoz Biologics
Published on 06/27/2026 at 16:50, 3 hours 1 minute ago Redwood AI Announces Definitive Agreement with Quantum.IQ and Expands into Quantum Resistant Cyber Security
Published on 06/27/2026 at 01:40, 18 hours 11 minutes ago Polaris Renewable Energy Announces Results of Director Elections at Annual and Special Meeting
Published on 06/27/2026 at 00:00, 19 hours 51 minutes ago Onco-Innovations Initiates Three-Species Hepatocyte and Microsome Metabolism Studies for ONC010
Published on 06/26/2026 at 23:00, 20 hours 51 minutes ago Canadian North Resources Inc. Announces Results of 2026 Annual General and Special Shareholders Meeting
Published on 06/26/2026 at 22:50, 21 hours 1 minute ago Banyan Gold Files Technical Report for AurMac Project, Yukon, Canada
Published on 06/27/2026 at 00:05, 19 hours 45 minutes ago EAN Congress: Hearing aid use linked to 23% lower dementia risk in people with both epilepsy and hearing loss
Published on 06/27/2026 at 00:04, 19 hours 46 minutes ago Persistent and Nagarro sign Business Combination Agreement to form the Persistent - Nagarro Group, a global leader in AI-led digital engineering
Published on 06/26/2026 at 23:36, 20 hours 15 minutes ago Persistent and Nagarro sign Business Combination Agreement to form the Persistent – Nagarro Group, a global leader in AI-led digital engineering
Published on 06/26/2026 at 23:36, 20 hours 15 minutes ago EQS-Adhoc: Nagarro SE: Nagarro signs business combination agreement with Persistent Systems and supports voluntary public takeover offer to all shareholders at EUR 81 per share
Published on 06/26/2026 at 23:27, 20 hours 23 minutes ago EQS-WpÜG: Takeover Offer / Target company: Nagarro SE; Bidder: Galaxy Germany Holding SE
